Panbela to Host First Quarter 2023 Earnings Conference Call on May 4, 2023
MINNEAPOLIS, April 24, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the...
Clinical Trial
Pharma Two B to Present Additional Positive Results from P2B001 Phase 3 Trial at 2023 American Academy of Neurology Annual Meeting
Results showed P2B001, a once-daily fixed-dose combination of low dose pramipexole and low dose rasagiline, showed comparable efficacy to marketed...
Lexicon To Present Results From LX9211 Phase 2 Trial In Postherpetic Neuralgia At The 2023 American Academy Of Neurology (AAN) Annual Meeting And The British Pain Society (BPS) 56th Annual Scientific Meeting 2023
Data accepted as AAN Late-Breaking AbstractTHE WOODLANDS Texas, April 21, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today...
LianBio Promotes Pascal Qian to Chief Commercial Officer
SHANGHAI, China and PRINCETON, N.J., April 21, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing...
CymaBay Therapeutics Announces Publication of Results From the ENHANCE, Phase 3 Study of Seladelpar in Patients with Primary Biliary Cholangitis (PBC)
NEWARK, Calif., April 21, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and...
Ocuphire Appoints Rick Rodgers as Interim Chief Executive Officer
Seasoned operating executive with successful track record at late-stage biopharmaceutical companiesFARMINGTON HILLS, Mich., April 21, 2023 (GLOBE NEWSWIRE) -- Ocuphire...
LianBio Announces China National Medical Products Administration (NMPA) Acceptance with Priority Review of New Drug Application for Mavacamten for the Treatment of Patients with Obstructive Hypertrophic Cardiomyopathy
SHANGHAI, China and PRINCETON, N.J., April 21, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing...
Axsome Therapeutics to Present Five Abstracts Including New Data from the Positive SHARP Study of SUNOSI® (solriamfetol) in Participants with Cognitive Impairment with Excessive Daytime Sleepiness in Obstructive Sleep Apnea at the 2023 American Academy of Neurology (AAN) Annual Meeting
NEW YORK, April 21, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel...
Apellis Announces Validation of Four Marketing Applications for Pegcetacoplan for Geographic Atrophy
Applications are under review in Canada, Australia, the United Kingdom, and SwitzerlandApproval decisions expected in the first half of 2024WALTHAM,...
Freeline Announces Proposed ADS Ratio Change
LONDON, April 21, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that it plans to change...
Pixium Vision announces its consolidated financial statements for the financial year 2022 and the consolidated cash balance for March 31, 2023
Pixium Vision announces its consolidated financial statements for the financial year 2022 and the consolidated cash balance for March 31,...
Genmab Announces Initial Resolution of Its Second Arbitration Under License Agreement with Janssen
Company Announcement COPENHAGEN, Denmark; April 21, 2023 – Genmab A/S (Nasdaq: GMAB) announced today an award in the second arbitration...
Corvus Pharmaceuticals to Provide Business Update and Report First Quarter 2023 Financial Results on May 8, 2023
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PTBURLINGAME, Calif., April 20, 2023 (GLOBE...
Novan to Host Analyst and Investor Event: A Discussion of Molluscum’s Unmet Need with Pediatric Dermatologist Jeffrey Sugarman, MD, PhD
Live moderated webcast with members of the Novan management team and dermatological key opinion leader, Dr. Jeffrey Sugarman on Tuesday,...
Kineta, Inc. Announces $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
SEATTLE, April 20, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA) (the “Company” or “Kineta”), a clinical-stage biotechnology company focused...
SELLAS Life Sciences Successfully Completes Phase I Trial Dose Escalation of Novel, Highly Selective CDK9 Inhibitor GFH009 in Acute Myeloid Leukemia
– GFH009 showed strong anti-tumor effect and clinical and biological efficacy; PK profile supports anticipated once weekly dosing – – GFH009...
Windtree Therapeutics Announces Pricing of Upsized $10.8 Million Underwritten Public Offering
WARRINGTON, Pa., April 20, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company...
BioVie To Present Data from NE3107 Phase 2 Open-Label Trial at Society of Biological Psychiatry Annual Meeting
CARSON CITY, Nev., April 20, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company...
Salarius Pharmaceuticals Presents Compelling Data in Two SP-3164 Targeted Protein Degrader Posters at the American Association for Cancer Research Annual Meeting
SP-3164 demonstrates compelling antitumor activity in animal models of follicular lymphoma and compelling antitumor activity in animal models of multiple...
ContraFect Data Presentations at the 33rd Annual ECCMID Meeting Highlight the Potential Efficacy of Lysin CF-370 Against Antibiotic Resistant Gram-negative Pathogens
YONKERS, N.Y., April 20, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery...